Lani
03-29-2006, 10:49 AM
not YET RECRUITING, BUT IN THE WORKS:
Fresenius Biotech GmbH, Clinical Development, Frankfurter Ring 193a, 80807 München, Germany
Tel: +49 (0)89/30 65 93 17, e-mail: clinicalstudies@fresenius-biotech.com - 4 -
Metastatic Breast Cancer
Status:
Phase II study on the trifunctional antibody ertumaxomab (anti HER2/neu x anti CD3) in
patients with hormonal receptor positive and HER/2 expressing (1+ and 2+) advanced or
metastatic breast cancer.
phase II
Her2/neu positive metastatic breast cancer patients not qualifying for treatment with
Herceptin and failing anti-hormonal therapies
ertumaxomab (anti Her2 x anti CD3)
Fresenius Biotech GmbH
Tel: +49-(0)89-306 593-17
Email: clinicalstudies@fresenius-biotech.com
Not yet recruiting
The clinical trials are conducted in collaboration with TRION Pharma.
LOOK UP FRESENIUS BIOTECH IN GOOGLE TO SEARCH FOR WEBSITE
HOPE THIS HELPS!
Lani
Fresenius Biotech GmbH, Clinical Development, Frankfurter Ring 193a, 80807 München, Germany
Tel: +49 (0)89/30 65 93 17, e-mail: clinicalstudies@fresenius-biotech.com - 4 -
Metastatic Breast Cancer
Status:
Phase II study on the trifunctional antibody ertumaxomab (anti HER2/neu x anti CD3) in
patients with hormonal receptor positive and HER/2 expressing (1+ and 2+) advanced or
metastatic breast cancer.
phase II
Her2/neu positive metastatic breast cancer patients not qualifying for treatment with
Herceptin and failing anti-hormonal therapies
ertumaxomab (anti Her2 x anti CD3)
Fresenius Biotech GmbH
Tel: +49-(0)89-306 593-17
Email: clinicalstudies@fresenius-biotech.com
Not yet recruiting
The clinical trials are conducted in collaboration with TRION Pharma.
LOOK UP FRESENIUS BIOTECH IN GOOGLE TO SEARCH FOR WEBSITE
HOPE THIS HELPS!
Lani